Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria

Publication date: January 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 1Author(s): Elisabetta Di Leo, Gianfranco Calogiuri, Luigi Macchia, Eustachio Nettis
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research

Related Links:

This study — known as the Learning Early About Peanut or LEAP trial — showed that children at high risk of developing peanut allergies who are introduced to peanuts at 4 months to 6 months old had a significantly lower risk of developing a peanut allergy than those who waited until they were 5 years; 1.9% of the kids who had peanuts early developed an allergy, compared with 13.7% of the kids who waited. The LEAP trial formed the basis for Monday’s new recommendations, which encourage the early introduction of peanut products in infants at high risk for allergies. But most babies are not at high risk, and ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News CNN Food Allergies Source Type: news
Conclusions: This is the first study to examine the efficacy of a CRTh2 antagonist in antihistamine-refractory CSU. AZD1981 treatment was well tolerated, effectively inhibited PGD2-mediated eosinophil shape change, shifted numbers of circulating eosinophils, and reduced weekly itch scores more than hives during treatment and into washout. Further studies are needed to determine whether inhibition of the PGD2/CRTh2 pathway will be an ­effective treatment for CSU.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - Category: Allergy & Immunology Source Type: research
Rituximab is a chimeric monoclonal anti-CD20 antibody with wide use in cancer (lymphoma) and connective tissue diseases (rheumatoid arthritis, and vasculitis)1. Hypersensitivity reactions to rituximab can range from type I IgE-mediated reaction (urticaria, shortness of breath, hypotension, or anaphylaxis), to cytokine-mediated reaction (fevers, chills, rigors), or a mix of both, thus limiting the use of rituximab as first line therapy for many cases. Desensitization is a new therapeutic approach which can be performed with rituximab to offset these reactions.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Challenging Clinical Cases Source Type: research
There is increasing evidence pointing to the important role of tumor necrosis factor-alpha (TNF- α), a key inflammatory and apoptotic mediator in urticarial inflammation. However, the role of the TNF-α system a...
Source: Allergy, Asthma and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Research Source Type: research
We present the first case of a delayed, protracted allergic reaction to oral viscous lidocaine with positive intradermal testing.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research
Title: loratadine, Claritin, Claritin RediTabs, Alavert, Claritin Hives Relief, Children's ClaritinCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 3/7/2019 12:00:00 AM
Source: MedicineNet Allergies General - Category: Allergy & Immunology Source Type: news
We describe the case of a 48-year-old woman suffering from EoE not responsive to the topical steroid administration and diagnosis of SNAS. The patient started nickel oral desensitization according to the literature protocol continuing nickel-free diet. After 1 year from the beginning of the treatment, during the maintenance dose (500 ng three times a week), she decreased gradually the dosage of immunotherapy and reintroduced all the culprit foods. After the immunotherapy interruption, during the free diet, she repeated the oesophagogastroscopy with a complete macroscopic and histological resolution. We showed...
Source: International Journal of Immunopathology and Pharmacology - Category: Allergy & Immunology Tags: Int J Immunopathol Pharmacol Source Type: research
The basis of venom immunotherapy (VIT) can be defined as protection against IgE-mediated immunologic mechanisms such as anaphylaxis.1,2 Most insect stings produce local reactions of swelling, pain, erythema and pruritus, typically peaking by 24-48 hours and resolving within 3-10 days.5 Unfortunately, some patients experience systemic reactions ranging from cutaneous reactions only (characterized by urticaria and/or angioedema, excluding throat, larynx and tongue) to life-threatening systemic anaphylactic reactions (SAR).
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research
A 27-year-old female patient with a history of hereditary angioedema (HAE), diagnosed at the age of 15 years, is routinely followed-up in Immunology clinic. She initially presented with a 3-year history of recurrent angioedema of the extremities and episodic acute abdominal pain with nausea and vomiting. Although there was no clear family history of HAE, she noted that her father had experienced swelling of the hand years before but had not sought medical attention for this. Both parents were advised to have C1 esterase inhibitor level and function tested however, have not yet done so.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Clinical Pearls Source Type: research
Source: Journal of Asthma and Allergy - Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
More News: Allergy | Allergy & Immunology | Hives | Xolair